Swedish cancer diagnostics company BiBBInstruments AB (Spotlight Stock Market: BIBB) said on Thursday it has signed its first European commercial distribution agreement for its powered endoscopic biopsy system EndoDrill GI with European healthcare and medical technology distribution group Palex Medical S.A.U. in Spain.
The deal grants Palex Spain exclusive rights to market and sell EndoDrill GI nationally and is intended to support wider expansion across the Palex network. The agreement covers EndoDrill GI only, with scope to add further products as they become commercially available.
Commercial launch activities in Spain have begun. EndoDrill GI has already been used in patient cases at endoscopic ultrasound centres in Madrid and Valladolid, providing early clinical experience to support market development.
EndoDrill GI is a powered biopsy instrument for endoscopic ultrasound with FDA 510(k) clearance and CE marking. It uses a rotating needle tip to obtain intact core tissue samples for histopathology and molecular analysis and is currently being commercialised in the United States through TaeWoong Medical USA.
Citius Oncology reports growing LYMPHIR adoption and market access
Summit Therapeutics expands ivonescimab programme into bladder cancer with Phase II/III trial
Lilly secures FDA Breakthrough Therapy designation for olomorasib in pancreatic cancer
Genprex collaborates with Roche Diagnostics on NSCLC biomarker validation
Zai Lab's zoci receives FDA orphan designation for neuroendocrine carcinomas
CelLBxHealth study highlights Parsortix potential in ADC biomarker monitoring
Coiled Therapeutics doses first patient with optimised AO-252 formulation
GlycoNex commences dosing in Phase I trial of GNX1021 in Japan
IMPACT Therapeutics grants Pharmanovia exclusive rights to senaparib across 66 countries
Datroway approved in EU for first-line metastatic triple-negative breast cancer
Karyopharm reports topline Phase 3 trial results in endometrial cancer
Proteotype unveils Alchemi platform for blood-based multi-cancer test Enlighten
10x Genomics and Lausanne University Hospital to collaborate on cancer care research